Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Coverage (5)
- Capricor’s DMD Therapy Gets Lancet Backing Ahead Of August FDA Showdown Yahoo Finance · 15h ago
- FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute Fierce Biotech · 15h ago
- FDA panel votes against Capricor's Duchenne heart disease therapy Reuters · 15h ago
- FDA expert panel recommends against approval of Capricor’s Duchenne drug STAT · 15h ago
- Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial The Lancet · 15h ago
What happened
"Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by Archynetys so far.
Outlets currently covering the story include Yahoo Finance, Fierce Biotech, Reuters and STAT. Archynetys measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by Archynetys's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by Archynetys's extractive engine from coverage metadata only — no AI-written claims. Updated 1h ago.
Questions people are asking
Why is "Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystroph" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst Archynetys classifies as a trend.
How does Archynetys measure this trend?
Archynetys scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plunging after FDA staff disputed the company's claims regarding Phase 3 success for its DMD cell therapy.
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares plunged after FDA staff flagged data and efficacy concerns regarding its Duchenne heart disease therapy.